Oncology Drug Snapshot: Axitinib (Inlyta)

Slideshow

This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

Related Videos
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content
Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.

Pembrolizumab Prolongs Survival in Clear-Cell RCC

April 18th 2024
Article

Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.

Taplin’s Key to a Successful GU Career: “Always Finish” What You Start

March 28th 2024
Article

Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.

Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.

Oncology On-The-Go Podcast: Integrative and Palliative Kidney Cancer Care

March 28th 2023
Podcast

Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.

Practices should not differentiate treatment options based on race for patients with metastatic renal cell carcinoma, according to Jasmeet Kaur, MD.

Comparable Findings in White and Black Populations for ICI Use in Metastatic RCC

February 20th 2024
Article

Practices should not differentiate treatment options based on race for patients with metastatic renal cell carcinoma, according to Jasmeet Kaur, MD.

Interim findings from a phase 3 trial support adjuvant pembrolizumab as a new therapeutic option for those with muscle-invasive urothelial carcinoma at high risk of recurrence.

Pembrolizumab Improves DFS Vs Observation in Muscle-Invasive Urothelial Carcinoma

February 8th 2024
Article

Interim findings from a phase 3 trial support adjuvant pembrolizumab as a new therapeutic option for those with muscle-invasive urothelial carcinoma at high risk of recurrence.